Biological functional relevance of asymmetric dimethylarginine (ADMA) in cardiovascular disease

International Journal of Molecular Sciences

Volumn 14, Issue 12, 2013, Pages 24412-24421

  Franceschelli, Sara ^a   Ferrone, Alessio ^a   Pesce, Mirko ^a   Riccioni, Graziano ^b   Speranza, Lorenza ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

Author keywords

ADMA; Cardiovascular disease; Nitric oxide

Indexed keywords

6 N, N' DIMETHYLARGININE; ALANINE GLYOXYLATE AMINOTRANSFERASE; MATRIX METALLOPROTEINASE; N (G) METHYLARGININE; N (G), N (G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; PROTEIN ARGININE METHYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EDITORIAL; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; HUMAN; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN TRANSPORT; PULMONARY HYPERTENSION; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; ARGININE; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RISK FACTORS;

EID: 84890445251     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141224412     Document Type: Editorial

References (45)

1. Naseem, K.M. The role of nitric oxide in cardiovascular diseases. Mol. Aspects Med. 2005, 26, 33-65.
2. Napoli, C.; Ignarro, L.J. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch. Pharm. Res. 2009, 32, 1103-1108.
3. Antoniades, C.; Shirodaria, C.; Leeson, P.; Antonopoulos, A.; Warrick, N.; van Assche, T.; Cunnington, C.; Tousoulis, D.; Pillai, P.; Ratnatunga, C., et al. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: Implications for endothelial function in human atherosclerosis. Eur. Heart J. 2009, 30, 1142-1150.
4. Olken, N.M.; Marletta, M.A. NG-methyl-L-arginine functions as an alternate substrate and mechanism-based inhibitor of nitric oxide synthase. Biochemistry 1993, 32, 9677-9685.
5. Fickling, S.; Leone, A.; Nussey, S.; Vallance, P.; Whitley, G. Synthesis of NG, NG dimethylarginine by human endothelial cells. Endothelium 1993, 1, 137-140.
6. Bedford, M.T.; Clarke, S.G. Protein arginine methylation in mammals: Who, what, and why. Mol. Cell 2009, 33, 1-13.
7. Palm, F.; Onozato, M.L.; Luo, Z.; Wilcox, C.S. Dimethylargininedimethylaminohydrolase (DDAH): Expression, regulation, and function in the cardiovascular and renal systems. Am. J. Physiol. Heart Circ. Physiol. 2007, 293, H3227-H3245.
8. Rodionov, R.N.; Murry, D.J.; Vaulman, S.F.; Stevens, J.W.; Lentz, S.R. Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. J. Biol. Chem. 2010, 285, 5385-5391.
9. Closs, E.I.; Boissel, J.P.; Habermeier, A.; Rotmann, A. Structure and function of cationic amino acid transporters (CATs). J. Membr. Biol. 2006, 213, 67-77.
10. Davids, M.; van Hell, A.J.; Visser, M.; Nijveldt, R.J.; van Leeuwen, P.A.; Teerlink, T. Role of the human erythrocyte in generation and storage of asymmetric dimethylarginine. Am. J. Physiol. Heart Circ. Physiol. 2012, 302, H1762-H1770.
11. Billecke, S.S.; Kitzmiller, L.A.; Northrup, J.J.; Whitesall, S.E.; Kimoto, M.; Hinz, A.V.; D'Alecy, L.G. Contribution of whole blood to the control of plasma asymmetrical dimethylarginine. Am. J. Physiol. Heart Circ. Physiol. 2006, 291, 1788-1796.
12. Iarlori, C.; Gambi, D.; Lugaresi, A.; Patruno, A.; Felaco, M.; Salvatore, M.; Speranza, L.; Reale, M. Reduction of free radicals in multiple sclerosis: Effect of glatiramer acetate (Copaxone). Mult. Scler. 2008, 14, 739-748.
13. Felaco, M.; di Maio, F.D.; de Fazio, P.; D'Arcangelo, C.; de Lutiis, M.A.; Varvara, G.; Grilli, A.; Barbacane, R.C.; Reale, M.; Conti, P. Localization of the e-NOS enzyme in endothelial cells and odontoblasts of healthy human dental pulp. Life Sci. 2000, 68, 297-306.
14. Franceschelli, S.; Pesce, M.; Vinciguerra, I.; Ferrone, A.; Riccioni, G.; Patruno, A.; Grilli, A.; Felaco, M.; Speranza, L. Licocalchone-C extracted from Glycyrrhiza glabra inhibits lipopolysaccharide-interferon-γ inflammation by improving antioxidantconditions and regulating inducible nitric oxide synthase expression. Molecules 2011, 16, 5720-5734.
15. Grilli, A.; de Lutiis, M.A.; Patruno, A.; Speranza, L.; Gizzi, F.; Taccardi, A.A.; di Napoli, P.; de Caterina, R.; Conti, P.; Felaco, M. Inducible nitric oxide synthase and heme oxygenase-1 in rat heart: Direct effect of chronic exposure to hypoxia. Ann. Clin. Lab. Sci. 2003, 33, 208-215.
16. Speranza, L.; Franceschelli, S.; Pesce, M.; Ferrone, A.; Patruno, A.; Riccioni, G.; de Lutiis, M.A.; Felaco, M.; Grilli, A. Negative feedback interaction of HO-1/INOS in PBMC of acute congestive heart failure patients. J. Biol. Regul. Homeost. Agents 2013, 27, 739-748.
17. Han, J.; Shuvaev, V.V.; Muzykantov, V.R. Targeted interception of signaling reactive oxygen species in the vascular endothelium. Ther. Deliv.2012, 3, 263-276.
18. Kampoli, A.M.; Tousoulis, D.; Tentolouris, C.; Stefanadis, C. Novel agents targeting nitric oxide. Curr. Vasc. Pharmacol. 2012, 10, 61-76.
19. Sharshar, T.; Gray, F.; Lorin de la Grandmaison, G.; Hopkinson, N.S.; Ross, E.; Dorandeu, A.; Orlikowski, D.; Raphael, J.C.; Gajdos, P.; Annane, D. Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. Lancet 2003, 362, 1799-1805.
20. Speranza, L.; Franceschelli, S.; Pesce, M.; Vinciguerra, I.; de Lutiis, M.A.; Grilli, A.; Felaco, M.; Patruno, A. Phosphodiesterase type-5 inhibitor and oxidative stress. Int. J. Immunopathol. Pharmacol. 2008, 21, 879-889.
21. Caplin, B.; Leiper, J. Endogenous nitric oxide synthase inhibitors in the biology of disease: Markers, mediators, and regulators? Arterioscler. Thromb. Vasc. Biol. 2012, 32, 1343-1353.
22. Riccioni, G.; Speranza, L.; Scotti, L.; Bucciarelli, V.; di Ilio, E.; D'Orazio, N.; Pesce, M.; Aceto, A.; Sorrenti, V.; Frigiola, A., et al. The effect of pharmacological treatment on ADMA in patients with heart failure. Front. Biosci. (Elite Ed.) 2011, 3, 1310-1314.
23. Ueda, S.; Yamagishi, S.; Matsumoto, Y.; Fukami, K.; Okuda, S. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin. Exp. Nephrol. 2007, 11, 115-121.
24. Galal, O.; Podlogar, J.; Verspohl, E.J. Impact of ADMA (asymmetric dimethylarginine) on physiology with respect to diabetes mellitus and respiratory system BEAS-2B cells (human bronchial epithelial cells). J. Pharm. Pharmacol. 2013, 65, 253-263.
25. Ghebremariam, Y.T.; Erlanson, D.A.; Cooke, J.P. A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: A modulator of cardiovascular nitric oxide. J. Pharmacol. Exp. Ther. 2013, doi:10.1124/jpet.113.206847.
26. Labruijere, S.; van Houten, E.L.; de Vries, R.; Musterd-Bagghoe, U.M.; Garrelds, I.M.; Kramer, P.; Danser, A.H.; Villalón, C.M.; Visser, J.A.; van den Brink, A.M. Analysis of the vascular responses in a murine model of polycystic ovary syndrome. J. Endocrinol. 2013, 218, 205-213.
27. Beutel, G.; Perthel, R.; Suntharalingam, M.; Bode-Böger, S.M.; Martens-Lobenhoffer, J.; Kielstein, J.T.; Kielstein, H. Effect of chronic elevated asymmetric dimethylarginine (ADMA) levels on granulopoiesis. Ann. Hematol. 2013, 92, 505-508.
28. Ghebremariam, Y.T.; Yamada, K.; Lee, J.C.; Johnson, C.L.; Atzler, D.; Anderssohn, M.; Agrawal, R.; Higgins, J.P.; Patterson, A.J.; Böger, R.H., et al. FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl rats. PLoS One 2013, 8, e60653.
29. Li Volti, G.; Salomone, S.; Sorrenti, V.; Mangiameli, A.; Urso, V.; Siarkos, I.; Galvano, F.; Salamone, F. Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice. Cardiovasc. Diabetol. 2011, 10, 62.
30. Li Volti, G.; Sorrenti, V.; Acquaviva, R.; Murabito, P.; Gullo, A.; Barcellona, M.L.; Galvano, F.; Rodella, L.; Rezzani, R.; Vanella, L.; et al. Effect of ischemia-reperfusion on renal expression and activity of N(G)-N(G)-dimethylarginine dimethylaminohydrolases. Anesthesiology 2008, 109, 1054-1062.
31. Speranza, L.; Franceschelli, S.; D'Orazio, N.; Gaeta, R.; Bucciarelli, T.; Felaco, M.; Grilli, A.; Riccioni, G. The biological effect of pharmacological treatment on dimethylaminohydrolases (DDAH-1) and cationic amino acid transporter-1 (CAT-1) expression in patients with acute congestive heart failure. Microvasc. Res. 2011, 82, 391-396.
32. Davids, M.; Teerlink, T. Plasma concentrations of arginine and asymmetric dimethylarginine do not reflect their intracellular concentrations in peripheral blood mononuclear cells. Metabolism 2013, 62, 1455-1461.
33. Haghikia, A.; Podewski, E.; Libhaber, E.; Labidi, S.; Fischer, D.; Roentgen, P.; Tsikas, D.; Jordan, J.; Lichtinghagen, R.; von Kaisenberg C.S.; et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res. Cardiol. 2013, 108, 366.
34. Riccioni, G.; D'Orazio, N.; Salvatore, C.; Franceschelli, S.; Pesce, M.; Speranza, L. Carotenoids and vitamins C and E in the prevention of cardiovascular disease. Int. J. Vitam. Nutr. Res. 2012, 82, 15-26.
35. Speranza, L.; Pesce, M.; Franceschelli, S.; Bucciarelli, T.; Gallina, S.; Riccioni, G.; Patruno, A.; Felaco, M. The biological evaluation of ADMA/SDMA and eNOS in patients with ACHF. Front. Biosci. (Elite Ed.) 2013, 5, 551-557.
36. Szlachcic, A.; Krzysiek-Maczka, G.; Pajdo, R.; Targosz, A.; Magierowski, M.; Jasnos, K.; Drozdowicz, D.; Kwiecien, S.; Brzozowski, T. The impact of asymmetric dimethylarginine (ADMA), the endogenous nitric oxide (NO) synthase inhibitor, to the pathogenesis of gastric mucosal damage. Curr. Pharm. Des. 2013, 19, 90-97.
37. Sydow, K.; Hornig, B.; Arakawa, N.; Bode-Böger, S.M.; Tsikas, D.; Münzel, T.; Böger, R.H. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: Potential role of ADMA. Vasc. Med. 2004, 9, 93-101.
38. Dimitroulas, T.; Giannakoulas, G.; Sfetsios, T.; Karvounis, H.; Dimitroula, H.; Koliakos, G.; Settas, L. Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. Rheumatology 2008, 47, 1682-1685.
39. Sorrenti, V.; Mazza, F.; Campisi, A.; Vanella, L.; Li Volti, G.; di Giacomo, C. High glucose-mediated imbalance of nitric oxide synthase and dimethylargininedimethylaminohydrolase expression in endothelial cells. Curr. Neurovasc. Res. 2006, 3, 49-54.
40. Mohan, S.; Fung, H.L. Mechanism of cellular oxidation stress induced by asymmetric dimethylarginine. Int. J. Mol. Sci. 2012, 13, 7521-7531.
41. Aldámiz-Echevarría, L.; Andrade, F. Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int. J. Mol. Sci. 2012, 13, 11288-11311.
42. Cao, Y.; Mu, J.J.; Fang, Y.; Yuan, Z.Y.; Liu, F.Q. Impact of high salt independent of blood pressure on PRMT/ADMA/DDAH. Pathway in the aorta of dahl salt-sensitive rats. Int. J. Mol. Sci. 2013, 14, 8062-8072.
43. Antoniades, C.; Demosthenous, M.; Tousoulis, D.; Antonopoulos, A.S.; Vlachopoulos, C.; Toutouza, M.; Marinou, K.; Bakogiannis, C.; Mavragani, K.; Lazaros, G., et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension 2011, 58, 93-98.
44. Zuccalà, A.; Fiorenza, S.; Rapanà, R.; Santoro, A. Hypertension, atherosclerosis and kidney. G. Ital. Nefrol. 2005, 22 (Suppl. 31), S9-S14.
45. Hsu, C.P.; Lin, S.J.; Chung, M.Y.; Lu, T.M. Asymmetric dimethylarginine predicts clinical outcomes in ischemic chronic heart failure. Atherosclerosis 2012, 225, 504-510.